At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 54 enrolled
Drug / intervention
Pregabalindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Mar 19, 2007·Updated Jan 25, 2021
In Brief
A Phase 3 clinical trial evaluating Pregabalin for Epilepsies, Partial. Completed, enrolled 54 participants across 18 sites in 3 countries.
Detailed Summary
The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsies, Partial
CountriesMexico, South Korea, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMay 2007
Primary CompletionOct 2013
TodayJul 2026
First PostedMar 19, 2007
Enrollment StartMay 1, 2007
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 19.3 years ago
Interventions
Pregabalindrug
Orally-administered pregabalin